65 results about "Cluster of differentiation" patented technology

The present invention relates to the use of cluster of differentiation (CD) molecules in detecting the presence and progression of one or more disease states in an individual. In particular it relates to the use of profiles of shed CD (sCD) molecules in detecting and assessing the progression of one or more disease states in an individual. Further uses of sCD profiles according to the present invention are also described.

The invention belongs to the field of genetic engineering and particularly relates to an anti-CD123 single-chain antibody, a chimeric antigen receptor combined by the same, and application thereof. The anti-CD123 single-chain antibody is a CD123 antigen-recognizing peptide with an amino acid sequence shown as SEQ ID NO: 1. The anti-CD123 antigen chimeric antigen receptor is formed by sequentiallyconnecting the CD123 antigen-recognizing peptide (ScFv), a hinge region, a transmembrane region and an intracellular signal region. When being expressed in immune cells, the anti-CD123 antigen chimeric antigen receptor can not only effectively eliminate target tumor cells, which can express CD123 antigens, without toxicity to tumor cell with negative antigens/incapable of expressing CD123, but also maintain the positive rate of a CD123-targeted antigen chimeric antigen receptor (CAR) during patient cell culturing, which can propagate for a long time after being stimulated by target antigens and accordingly achieves targeted treatment on tumors.

The invention relates to the field of biotechnology, in particular to an anti-EGFR (epidermal growth factor receptor) and anti-CD3 (cluster of differentiation 3) bispecific antibody and an application thereof. The bispecific antibody can be specifically bound with EGFR of tumor cell surface antigens and CD3, namely, CD3 molecules, of immune cell surface antigens; a single-chain antibody ScFv of an anti-CD3 antibody is located at the C terminal of a constant region of an anti-EGFR antibody. The invention further provides a preparation method of the bispecific antibody and a clinical application of the bispecific antibody. The bispecific antibody has higher affinity and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by EGFR overexpression.

The invention discloses a method for effectively culturing tumor infiltrating lymphocytes (TILs). The method comprises the following steps: extracting mononuclear cells from the pectoral ascite or tumor tissue of a patient, washing, inoculating into a culture bottle coated with recombinant human fibrin and cluster-of-differentiation-3 antibody, culturing for 24 hours, adding interleukin II, then using a serum-free culture medium containing the interleukin II and the supernatant pectoral ascite to enlarge and subculture every two or three days, and adding apoptosis-regulated protein survivin and mucoprotein-1 on the twelveth or thirteenth day to activate the killing activity; and harvesting cells on the fourteenth day. By adopting the method, the culture time, which is only 14 days, is greatly shortened, so that the hospital stays of the patient can be greatly shortened and the hospital burden of the patient can be reduced. Meanwhile, the problems that the cell proliferation speed is low and the proliferation ratio is low can be solved, thus the number of the cultured cells can meet the clinical requirement. The cultured TILs has strong cell specificity so as to enhance the clinical curative effect.

The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

The invention belongs to the technical field of genetic engineering antibodies, and particularly relates to a preparation and application of a bispecific antibody targeting a CD24 (cluster of differentiation 24) and activating NK cells (natural killer cells). According to the preparation and application of the bispecific antibody, an anti-CD24 humanized chimeric antibody cG7 and an MICA molecule capable of recruiting and activating the activity of the NK cells are connected through flexible peptide (Gly4Ser) and are stably transferred to a CHO-s eukaryotic expression system, and a stable high-expression cell strain is selected for propagation and expression of cG7-MICA; the bispecific antibody cG7-MICA utilizes the function of remodeling the MICA by utilizing the targeting effect of the cG7 to selectively display the MICA on the surface of a CD24+ tumor cell, the immune surveillance effect of the NK cells is induced, in addition, the NK cells are further activated through the effect ofan Fc part, and the antibody-dependent cell-mediated cytotoxicity (ADCC) is achieved; and through experimental verification, the immunocompetence of killing the CD24+ hepatocellular carcinoma cells is achieved in vitro and vivo.

The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain. e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.

The invention discloses a universal type lentivirus vector and a preparation method thereof, relates to a lentivirus vector and a preparation method thereof, and aims to solve the problems in a current CAR (Chimeric Antigen Receptor)-T preparation process that the vector construction steps are troublesome, the consumed time is too long, the lentivirus vector cannot be universally used, and the cost is high. The universal type lentivirus vector is characterized by taking pCDH-CMV-MCS-EF1-Puro plasmids as a framework and inserting the following elements of a CD8 (Cluster of Differentiation 8)alpha Leader DNA (Deoxyribose Nucleic Acid) sequence, a CD8alpha hinge region, a CD28 transmembrane region-intracellular region, a CD137 intracellular region and a CD3zeta in MCS (Multiple Cloning Sites) of the plasmid framework. The preparation method comprises the following steps: (1) designing a primer; (2) obtaining and activating a PBMNC (Peripheral Blood Mononulcear Cell); (3) extracting mRNA (Messenger Ribonucleic Acid) and carrying out an RT (Reverse Transcriptase) reaction; (4) preparing recombinant plasmids; (5) compounding a single-chain CD8alpha Leader DNA sequence; (6) connecting a linear vector, a target gene fragment and a CD8alpha Leader fragment, thus obtaining the universal type lentivirus vector. The preparation method disclosed by the invention is used for preparing the lentivirus vector.

The invention discloses ginseng derived nano-particles, as well as a preparation method and application thereof. The ginseng derived nano-particles have a membrane structure, wherein the particle size range is 150 to 500nm, and the peak particle size is 280 to 350nm. The ginseng derived nano-particle is prepared by performing centrifugation and filtering impurity removal for many times. By the ginseng derived nano-particle, a bone marrow derived monocyte-macrophage can be effectively induced to be proliferated and activated, meanwhile, multiple surfactant molecules such as a TLR2/4 (toll-like receptor 2/4) and a CD80 (cluster of differentiation 80) are up-regulated, and cell factors such as a TNF-a (tumor necrosis factor-a) and an IL-6 (interleukin-6) are secreted. The ginseng derived nano-particle has broad application prospect in development of a medicament for preparing a natural immunoenhancer.

The invention relates to the technical field of genetic engineering and protein engineering, in particular to DNA for encoding a recombinant fusion protein of a variable fragment which contains a humanized CD19 (Cluster of Differentiation 19) antibody, the fusion protein encoded by the DNA, a production method for the fusion protein, and the application of the fusion protein. The invention provides the protein which comprises a humanized CD19 single-chain variable fragment, which can combine targeted B lymphoma cells with the CD19, cannot combine the targeted B lymphoma cells without the CD19, shows specific targeted binding activity, and has a very good application prospect.

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).

The invention belongs to the technical field of genetic engineering antibodies, in particular to a preparation method and application of a CD24 antibody fusion protein. The invention utilizes genetic engineering technology to link the CD24 humanized antibody hG7S with the extracellular 1-3 region of the MICA molecule through the G4S flexible peptide, and the mammalian eukaryotic expression system stably expresses hG7S-MICA; the CD24 antibody fusion protein hG7S-MICA can simultaneously Combined with CD24 molecules on the surface of tumor cells and the activated receptor NKG2D on the surface of NK cells, remodeling the immune surveillance effect of NK cells induced by NKG2D pathway on CD24+ tumor cells, and finally achieving the goal of activating the body's own immune system to effectively kill CD24+ tumor cells Purpose.

The invention discloses a Chinese medicinal preparation for treating acquired immune deficiency syndrome (AIDS) and a preparation method thereof. The Chinese medicinal preparation is prepared from the following raw materials of baical skullcap root, sophora flower, astragalus, Chinese angelica, siberian solomonseal rhizome, prepared rehmannia root, liquoric root, weeping forsythia, Chinese caterpillar fungus and citric acid in a weight ratio. The Chinese medicinal preparation has the effects of clearing heat and removing toxicity, strengthening body resistance to eliminate pathogenic factors,activating blood circulation and tonifying qi, is used for human immunodeficiency virus (HIV) infected persons and AIDS patients, has an effect of improving cluster of differentiation 4 (CD4) lymphocyte count, can reduce the HIV viral load of peripheral blood gradually, improve the symptoms of the patients obviously and improve liver functions of the patients, and does not have toxic or side effects of antiviral medicines in western medicines.

The invention mainly relates to the field of planting technology, and discloses a method for promoting the differentiation of Trichosanthes mellifera seedlings, including: selection and treatment of explants, preparation of medium, inoculation of explants, induction of differentiation and cultivation; Induced differentiation during basket tissue culture, after 16 days of culture in B5 medium, yellow-green cell protrusions began to appear, and then differentiated bud clusters appeared, which significantly shortened the time for induction of differentiation, improved planting efficiency, and increased economic income by 16.2%; As an explant, it will not cause damage to the Trichosanthes plant, does not affect the growth and results of Trichosanthes, and the source of young leaves is extensive, and tissue culture can be carried out at any time, and the planting efficiency is significantly improved; Salt water, acetic acid solution and nutrient solution treatment, avoid using too much disinfectant for repeated disinfection, save costs, and allow explants to continue absorbing and accumulating nutrients in a slightly acidic environment, speeding up the process of inducing differentiation of explants.

The invention relates to an anti-HIV gene engineering recombinant virus and a preparation method thereof, and an anti-HIV gene engineering medicament. The anti-HIV gene engineering recombinant virus comprises a constant region of a human antibody, and a cluster of differentiation 4 (CD4) and a chemokine receptor 5 (CCR5) which are connected with the constant region. The preparation method for the anti-HIV gene engineering recombinant virus comprises the steps as follows: obtaining a heavy chain constant region gene of the human antibody, a light chain constant region gene of the human antibody, a CD4 gene and a CCR5 gene; constructing a virus vector shuttle plasmid comprising the four genes; co-transforming the shuttle plasmid and a virus auxiliary plasmid to generate a recombinant virus plasmid; and transferring the recombinant virus plasmid to a cell strain for culturing and purifying the virus. The recombinant virus has both the CD4 and CCR5 capable of specifically binding with the CD4 site and CCR5 site of an HIV virus, an obviously enforced specific binding effect, and the function of doubly preventing the HIV virus from infecting a host cell. The preparation method is simple and practical. The anti-HIV gene engineering medicament with the recombinant virus can effectively act on the HIV virus, and can further effectively prevent and treat the infection of the HIV virus.

The invention discloses a CD4 (Cluster of Differentiation 4) cell chip which comprises a solid phase support and an antibody fixed on the support, wherein the antibody is a CD4 monoclonal antibody, and the solid phase support is a slide. The invention also discloses a preparation method of the CD4 cell chip, a CD4 cell assay kit containing the CD4 cell chip and a method for applying the CD4 cell chip to detection. The invention also discloses the application of the CD4 cell chip and the CD4 cell assay kit. The CD4 cell chip has the advantages of low cost and simple and convenient operation and is especially applicable to poverty-stricken zones seriously infected by AIDS viruses.

The invention relates to an immunohistochemical detection kit used for prognosis after hepatectomy. The immunohistochemical detection kit comprises a first antibody and a second antibody, the first antibody is two or combination of more than two selected from the following protein molecular markers of an antibody: CD33 (cluster of differentiation 33), CD11b (ITGAM), and CD169 (sialic acid adhesin). The kit employs a double antibody/tri-antibody combination index, prognosis condition of the patient after operation can be accurately predicted, so that appropriate treatment population and modes can be selected for doctors, and the kit provides more powerful support for effective diagnosis and treatment.

The invention provides a rat CD4 antibody coated magnetic beads, a preparation method and an application therefor and a kit containing magnetic beads. The method for preparing the magnetic beads comprises the following steps of: washing the magnetic beads multiple times through different reagents, and removing the supernatant. The rat CD4 antibody coated magnetic beads can be prepared according tothe preparation method. The prepared rat CD4 antibody coated magnetic beads can be used in the kit, and used for detecting immunological rejection after rat kidney transplantation. Compared with theprior art, the invention has the advantages that the rat CD4 antibody coated magnetic beads prepared by the method for preparing the rat CD4 antibody coated magnetic beads is combined with an immune cell function measurement kit ImmuKnow TW-Cylex , and can be used for detecting the immunological rejection after the rat kidney transplantation.

Methods and systems for diagnosing, providing prophylaxis, and treating one or more age-related neurodegeneration or pathological cognitive impairment are provided. An increased presence of CD103+ resident memory CD8+ T cells (CD8+ T_RM) can be detected in blood sample obtained from the human subjects with one or more symptoms of loss of short-term or long-term memory, decreased ability to maintain focus, and decreased problem-solving capacity. An increased presence of CD103+ CD8+ T_RM can be compared to a value obtained from one or a pool of healthy human subjects with none of the one or more symptoms. One or more of a therapeutically effective amount of: an inhibitor of cluster of differentiation (CD103), an inhibitor of perforin-1, and an inhibitor of interferon gamma (IFNγ) can be administered as treatment of age-related neurodegeneration or pathological cognitive impairment. Pathological neurodegeneration can include Parkinson's disease, multiple sclerosis, or Alzheimer' s disease.

The invention relates to a transformed and attenuated Listeria monocytogenes introducing a human CD24 (cluster of differentiation 24) nucleotide sequence, and a vaccine thereof. The transformed and attenuated Listeria monocytogenes is characterized in that human CD24 nucleotide is located on a shuttle plasmid PKSV7, and is duplicated and expressed in the attenuated Listeria monocytogenes or a progeny of the attenuated Listeria monocytogenes. The vaccine provided by the invention overcomes various defects in liver cancer treatment in the prior art, is used for clinic treatment and prevention of drug resistance of liver cancer to chemo-radiotherapeutic drugs and postoperative metastasis and relapse, and is relatively high in safety and reliability.